We serve (1R,3S,4R,5R)-4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol CAS:22422-34-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![(1R,3S,4R,5R)-4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol](https://a.dearchem.com/uploads/userup/0/15N3TB7-3127.png)
Chemical Name: ： (1R,3S,4R,5R)-4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol
CAS.NO:22422-34-0
Synonyms:
(-)-(1R,2R,3S,5R)-pinane-2,3-diol
(1R,2R,3S,5R)-2,6,6-Trimethylbicyclo[3.1.1]heptane-2,3-diol
(1R,2R,3S,5R)-(-)-Pinanediol
(-)-pinane-2,3-diol
(-)-2-Hydroxyisopinocampheol
(-)-cis-Pinane-cis-2,3-diol
(1R,2R,3S,5R)-2,3-Pinanediol
(1R,2R,3S,5R)-(-)-2,3-Pinanediol
Molecular Formula: C10H18O2
Molecular Weight:170.24900
Physical and Chemical Properties:
Density: 1.091g / cm3
Boiling point: 101-102ºC (1 mmHg)
Melting point: 55-59ºC
Flash point: 120.9ºC
Refractive index: 1.52
Specification:
Appearance: White solid
Purity:≥99%
Moisture Content: 0.1%
Impurity: 0.05%
Packing:
25kg cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Bortezomib CAS:179324-69-7
Contact us for information like (1R,3S,4R,5R)-4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(1R,2R,3S,5R)-(-)-2,3-Pinanediol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(1R,2R,3S,5R)-(-)-Pinanediol Use and application,(1R,2R,3S,5R)-(-)-Pinanediol technical grade,usp/ep/jp grade.
Related News: As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.N-(4-(naphthalen-1-yl)phenyl)-[1,1'-biphenyl]-4-amine manufacturer Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs.6-Iodo-1H-indazole supplier This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?Pyruvic acid vendor This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?The risk to the UK population has been raised from very low to low, according to Public Health England, which says the country is “well prepared for new diseases”.
